← Leaderboards
David Sultzer
Va Greater Los Angeles Healthcare System
$6,976,583
Attributed
$13,856,890
Total exposure
4
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $4.1M · FY2011–25$5M$3.8M$2.5M$1.3M$0
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$13,856,890 · 3
VA$0 · 1
By mechanism
R01$10,320,460 · 1
P30$3,536,430 · 2
I01$0 · 1
Top collaborators
- Michael G Agadjanyan5 shared
- Lon S Schneider5 shared
Others in their field
Top investigators on “Alzheimer&Apos”
- Jose A Luchsinger · Columbia University Health Sciences$56,595,040
- Eric M Reiman · Banner Health$48,982,487
- Yadong Huang · J. David Gladstone Institutes$40,311,515
- Lindsay A. Farrer · Boston University Medical Campus$34,189,802
- David M Holtzman · Washington University$28,985,806
- Michael W Weiner · Northern California Institute Res &Educ$28,197,224
Research focus
Alzheimer&AposS DiseaseParticipantPositron-Emission TomographyBrainImpaired CognitionAmyloidBiological MarkersClinical TrialsProgramsRandomizedPeripheral Blood Mononuclear CellBloodAmyloid Beta-ProteinPersonsTau ProteinsSamplingCognitiveClinical DataFollow-UpFutureResearch Project GrantsSymptomsPathology
Grant awards (15)
Safety/Tolerability/Immunogenicity of first-in-human Aβ DNA vaccine, AV-1959D Phase 1 trials in early-stage AD subjects: based on IND18953 cleared by FDA.$2,288,273
R01 · FY2025 · AG
Core B: Clinical Core$432,535
P30 · FY2025 · AG · contact PI
Safety/Tolerability/Immunogenicity of first-in-human Aβ DNA vaccine, AV-1959D Phase 1 trials in early-stage AD subjects: based on IND18953 cleared by FDA.$2,243,861
R01 · FY2024 · AG
Core B-Clinical Core$691,038
P30 · FY2024 · AG · contact PI
Safety/Tolerability/Immunogenicity of first-in-human Aβ DNA vaccine, AV-1959D Phase 1 trials in early-stage AD subjects: based on IND18953 cleared by FDA.$2,408,617
R01 · FY2023 · AG
Core B-Clinical Core$997,474
P30 · FY2023 · AG · contact PI
Manufacturing of New Batch AV-1959D Drug Product and Placebo for Phase 1 Trial$699,000
R01 · FY2023 · AG
Safety/Tolerability/Immunogenicity of first-in-human Aβ DNA vaccine, AV-1959D Phase 1 trials in early-stage AD subjects: based on IND18953 cleared by FDA.$2,680,709
R01 · FY2022 · AG
Core B-Clinical Core$676,054
P30 · FY2022 · AG · contact PI
Core B-Clinical Core$739,329
P30 · FY2021 · AG · contact PI
Cholinergic Receptors in Aging and Early Alzheimer's Disease: Longitudinal Change$0
I01 · FY2018 · VA · contact PI
Cholinergic Receptors in Aging and Alzheimers Disease Ligand Neuroimaging$0
I01 · FY2014 · VA · contact PI
Cholinergic Receptors in Aging and Alzheimers Disease Ligand Neuroimaging$0
I01 · FY2013 · VA · contact PI
Cholinergic Receptors in Aging and Alzheimers Disease Ligand Neuroimaging$0
I01 · FY2012 · VA · contact PI
Cholinergic Receptors in Aging and Alzheimers Disease Ligand Neuroimaging$0
I01 · FY2011 · VA · contact PI